Budget Impact of Oral Semaglutide Intensification versus Sitagliptin among US Patients with Type 2 Diabetes Mellitus Uncontrolled with Metformin

BACKGROUND: Oral semaglutide was approved in 2019 for blood glucose control in patients with type 2 diabetes mellitus (T2DM) and was the first oral glucagon-like peptide 1 receptor agonist (GLP-1 RA). T2DM is associated with substantial healthcare expenditures in the US, so the cost of a new interve...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Pharmacoeconomics
Autors principals: Wehler, Elizabeth, Lautsch, Dominik, Kowal, Stacey, Davies, Glenn, Briggs, Andrew, Li, Qianyi, Rajpathak, Swapnil, Alsumali, Adnan
Format: Artigo
Idioma:Inglês
Publicat: Springer International Publishing 2020
Matèries:
Original Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7882575/
https://ncbi.nlm.nih.gov/pubmed/33150566
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40273-020-00967-7
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars